CA521 FALA also demonstrated having a long half-life of 9.5 days in mice and 9.3 days in rhesus monkeys. CA521 FALA showed potent SARS-CoV-2-specific neutralization activity against SARS-CoV-2 pseudovirus and authentic SARS-CoV-2 infection in vitro. One human antibody, CA521 FALA, demonstrated neutralization potential by immunizing human antibody transgenic mice. Here we describe the identification of several monoclonal antibodies that target SARS-CoV-2 Spike protein. The SARS-CoV-2 Spike protein is considered a key therapeutic target by many researchers. There is currently no approved therapeutics for treating COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic, which has resulted in more than two million deaths at 2021 February.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |